These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 31212653)

  • 21. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
    Anantharaman A; Friedlander T; Lu D; Krupa R; Premasekharan G; Hough J; Edwards M; Paz R; Lindquist K; Graf R; Jendrisak A; Louw J; Dugan L; Baird S; Wang Y; Dittamore R; Paris PL
    BMC Cancer; 2016 Sep; 16(1):744. PubMed ID: 27658492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.
    Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH
    Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-Throughput Label-Free Isolation of Heterogeneous Circulating Tumor Cells and CTC Clusters from Non-Small-Cell Lung Cancer Patients.
    Zeinali M; Lee M; Nadhan A; Mathur A; Hedman C; Lin E; Harouaka R; Wicha MS; Zhao L; Palanisamy N; Hafner M; Reddy R; Kalemkerian GP; Schneider BJ; Hassan KA; Ramnath N; Nagrath S
    Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31947893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin.
    Po JW; Roohullah A; Lynch D; DeFazio A; Harrison M; Harnett PR; Kennedy C; de Souza P; Becker TM
    J Circ Biomark; 2018; 7():1849454418782617. PubMed ID: 30013673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of Ki67 and circulating tumor cells with an epithelial-mesenchymal transition phenotype in non-small cell lung cancer.
    Peng H; Tan X; Wang Y; Dai L; Liang G; Guo J; Chen M
    Am J Transl Res; 2020; 12(6):2916-2928. PubMed ID: 32655819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Programmed Death-Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC.
    Ancel J; Birembaut P; Dewolf M; Durlach A; Nawrocki-Raby B; Dalstein V; Delepine G; Blacher S; Deslée G; Gilles C; Polette M
    Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31546725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy.
    Papadaki MA; Sotiriou AI; Vasilopoulou C; Filika M; Aggouraki D; Tsoulfas PG; Apostolopoulou CA; Rounis K; Mavroudis D; Agelaki S
    Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
    Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
    PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epithelial/Mesenchymal Characteristics and PD-L1 Co-Expression in CTCs of Metastatic Breast Cancer Patients Treated with Eribulin: Correlation with Clinical Outcome.
    Polioudaki H; Mala A; Gkimprixi E; Papadaki MA; Chantziou A; Tzardi M; Mavroudis D; Agelaki S; Theodoropoulos PA
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33322610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
    Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
    World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterogeneity and prognosis of programmed cell death-ligand 1 expression in the circulating tumor cells of non-small cell lung cancer.
    Wang HL; Wu JQ; Wang Y; Yu J; Mao XN; Li ZR; Niu HR; Jin CL; Wang XJ; Yan ZH; Yi L; Yang B; Wei PJ; Zhang HT; Zhang SC
    Neoplasma; 2021 Jul; 68(4):823-831. PubMed ID: 34097427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epithelial-mesenchymal transition and GALC expression of circulating tumor cells indicate metastasis and poor prognosis in non-small cell lung cancer.
    Liu DG; Xue L; Li J; Yang Q; Peng JZ
    Cancer Biomark; 2018; 22(3):417-426. PubMed ID: 29758927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating tumor cell clusters are a potential biomarker for detection of non-small cell lung cancer.
    Manjunath Y; Upparahalli SV; Suvilesh KN; Avella DM; Kimchi ET; Staveley-O'Carroll KF; Li G; Kaifi JT
    Lung Cancer; 2019 Aug; 134():147-150. PubMed ID: 31319973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer.
    Funaki S; Shintani Y; Kawamura T; Kanzaki R; Minami M; Okumura M
    Oncol Rep; 2017 Oct; 38(4):2277-2284. PubMed ID: 28849209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System.
    Xu L; Mao X; Imrali A; Syed F; Mutsvangwa K; Berney D; Cathcart P; Hines J; Shamash J; Lu YJ
    PLoS One; 2015; 10(9):e0138032. PubMed ID: 26397728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
    Ikeda M; Koh Y; Teraoka S; Sato K; Oyanagi J; Hayata A; Tokudome N; Akamatsu H; Ozawa Y; Endo K; Higuchi M; Nakanishi M; Ueda H; Yamamoto N
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34064720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognosis value of circulating tumor cell PD‑L1 and baseline characteristics in patients with NSCLC treated with immune checkpoint inhibitors plus platinum‑containing drugs.
    Su X; Zhou C; Chen S; Ma Q; Xiao H; Chen Q; Zou H
    Oncol Lett; 2024 Mar; 27(3):131. PubMed ID: 38362233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer.
    Acheampong E; Abed A; Morici M; Spencer I; Beasley AB; Bowyer S; Asante DB; Lomma C; Lin W; Millward M; Gray ES
    Transl Lung Cancer Res; 2022 Mar; 11(3):440-451. PubMed ID: 35399573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune Checkpoint FGL1 Expression of Circulating Tumor Cells Is Associated With Poor Survival in Curatively Resected Hepatocellular Carcinoma.
    Yan Q; Lin HM; Zhu K; Cao Y; Xu XL; Zhou ZY; Xu LB; Liu C; Zhang R
    Front Oncol; 2022; 12():810269. PubMed ID: 35273912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1
    Zhang L; Zhang X; Liu Y; Zhang T; Wang Z; Gu M; Li Y; Wang DD; Li W; Lin PP
    Cancer Lett; 2020 Jan; 469():355-366. PubMed ID: 31678168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.